DESTINY-Breast03 Phase 3 Study Results
Phase I, Two-Part, Multi-Center, First-in-Human Study of
DS-6000a in Subjects with Advanced Renal Cell Carcinoma
and Ovarian Cancer
Erika P. Hamilton, MD1,2; Shekeab Jauhari, MD1,3; Kathleen Moore, MD4; Brian Rini, MD5; Robert McLeod, MD; Jie Lin, MD6;
Nanae Izumi6; Madan G. Kundu, PhD; Yusuke Myobatake; Abderrahmane Laadem, MD6; Yutaka Noguchi7; Julius Kirui¹;
David R. Spigel, MD1,2
1Sarah Cannon Research Institute, Nashville, TN; 2Tennessee Oncology, PLLC, Nashville, TN; ³Florida Cancer Specialists and Research Institute, Lake Mary, FL;
4University of Oklahoma College of Medicine, Oklahoma City, OK; 5Vanderbilt-Ingram Cancer Center, Nashville, TN; ‘Daiichi Sankyo, Inc, Basking Ridge, NJ;
7Daiichi Sankyo Co, Ltd, Tokyo, Japan
ASCO 2022 #3002 Oral
On behalf of the investigators
96
96
Daiichi-SankyoView entire presentation